The Dapivirine and Levonorgestrel MPT Ring: Understanding the Levonorgestrel Binding Reaction with Silicone Elastomer by Malcolm, Robert et al.
The Dapivirine and Levonorgestrel MPT Ring: Understanding the
Levonorgestrel Binding Reaction with Silicone Elastomer
Malcolm, R., Dallal Bashi, Y., McCoy, C., Murphy, D., Boyd, P., Devlin, B., & Kleinbeck, K. (2018). The
Dapivirine and Levonorgestrel MPT Ring: Understanding the Levonorgestrel Binding Reaction with Silicone
Elastomer. OA20.06. Abstract from HIV Research for Prevention 2018, Madrid, Spain.
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2018 HIVR4P. This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms
of use of the publisher
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:05. Apr. 2019
THURSDAY, 25 OCTOBER 
ORAL ABSTRACT SESSIONS
72HIV Research for Prevention 2018   hivr4p.org
Oral Abstract Session 20: Into the Future With Delivery Technologies
OA20.06
The Dapivirine and Levonorgestrel MPT Ring: 
Understanding the Levonorgestrel Binding 
Reaction with Silicone Elastomer
Karl Malcolm 1, Yahya Bashi 1, Clare McCoy 1, Diarmaid Murphy 1, Peter 
Boyd 1, Brid Devlin 2, Kyle Kleinbeck 2
1Queen’s University Belfast, United Kingdom, 2International 
Partnership for Microbicides, United States
Background: As part of ongoing efforts to refine and optimize a MPT 
vaginal ring (VR) releasing dapivirine (DPV) and levonorgestrel (LNG), 
we previously reported that LNG can irreversibly bind to addition 
cure silicone elastomers, with the extent of reaction dependent upon 
the cure time, cure temperature and the LNG particle size properties. 
Here, we further explore the LNG binding phenomenon using three 
custom silicone elastomers.
Methods: PROTO BSL 086 and Silbione® 4370 were supplied by 
Bluestar Silicone (York, USA). PROTO ESL 008 was provided by 
Elkem Silicones (Leverkusen, Germany). Micronised LNG was added 
and mixed into both parts A and B of each silicone system. Matrix-
type, silicone elastomer VRs (~8 g weight, 57 mm overall diameter, 
7.8 mm cross-sectional diameter) containing either 32 or 320 mg 
LNG with were manufactured by injection molding. The BSL 086 
VRs were cured at 70°C/1 min using pre-chilled PROTO BSL 086 
materials. The ESL 008 and 4370 VRs were cured at 105°C/1 min and 
140°C/2 min, respectively. Percentage LNG recovery was quantified 
by HPLC following acetone extraction. VRs were also exposed to 
various additional heat treatments, followed by LNG extraction and 
quantification. Acetone extracts and extracted rings were analysed 
by 1H-NMR.
Results: Low LNG assay indicating LNG reaction was also observed 
with the custom silicone elastomers. Mean LNG recoveries from 
32 and 320 mg rings were 70 and 99% (BSL 086), 55 and 91% 
(ESL 008) and 0.2 and 75 % for 4370 VRs, respectively. Additional 
LNG binding in the VRs was observed upon further heat treatment, 
giving insights into potential further losses of LNG during ring storage 
stability. 1H-NMR data provided direct evidence for the reaction 
product between the ethynyl group of LNG and silicone.
Conclusions: As with previously tested commercially available 
silicone elastomers, LNG binding was also observed with custom 
silicone elastomer materials. LNG recovery values were much higher 
with a 320 mg initial LNG loading compared to a 32 mg loading. 
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Innovative 3D Printed Intravaginal Rings: 
Reengineering Multipurpose Intravaginal Rings for 
Prevention of HIV and Unintended Pregnancy
S. Rahima Benhabbour 1,2, Rima Janusziewicz 1, Sue Mecham 1, Roopali 
Shrivastava 1, Panita Maturavongsadit 1, Denali Dahl 1, Kathleen L. 
Vincent 3, Audrie A. Medina-Colorado 3, Richard B. Pyles 3
1University of North Carolina, Chapel Hill, United States, 2UNC 
Eshelman School of Pharmacy, United States, 3University of Texas 
Medical Branch, United States
Background: Over 50% of HIV infected individuals are women, 
and ~50% of all pregnancies are unplanned. Therefore, there is a 
critical need to promote convenient, female-controlled methods of 
multipurpose prevention and delivery strategies. Intravaginal rings 
(IVRs) are well tolerated by women, are efficacious for contraception 
and hormone replacement therapy, and have high patient compliance. 
However, developing effective multipurpose IVRs is challenging due 
to the complexity of current engineering processes and differences 
in drug properties and release rates, thus mandating drug-specific 
customized IVR designs. Our goal is to address these limitations by 
revolutionizing the engineering process of IVRs using a state-of-the-
art 3D printing process known as the continuous liquid interface 
production (CLIP™). This versatile technology implements digital 
computer aided design combined with digital light synthesis to rapidly 
engineer geometrically complex 3D objects.
Methods: IVRs with complex geometries were fabricated with the 
CLIP technology. In vitro release of 3 antiretroviral drugs (ARVs) and 
4 contraceptives was assessed with 3D printed IVRs. In vitro and 
in vivo safety, including the effect on the vaginal microbiome was 
assessed with mouse size IVRs.
Results: IVRs with a range of designs, surface area, mechanical 
properties, and sizes were fabricated using the CLIP technology. 
We have demonstrated the ability to fine-tune release kinetics of 
contraceptive drugs (Ⱦ-estradiol, progesterone, EE, and ENG) and 
ARVs (DTG, TDF, and DLV). We have demonstrated the ability to co-
formulate multiple drugs in a single IVR with a range of designs. 3D 
CLIP IVRs were shown to be safe in vitro and in vivo, including limited 
impact on transplanted human vaginal microbiomes that colonized 
vaginal mucosal cultures.
Conclusions: 3D printing allows rapid manufacturing of custom-sized 
IVRs and IVRs that can integrate multiple drugs providing a novel 
cost-effective platform for the fine-tuned vaginal release of drugs. 
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